Assessing What Renewed Investment, Evolving Space Needs and Owner Strategy Mean For Massachusetts Life Sciences Sector

What You’ll Learn:

• With 76% of first half biotech venture dollars going to later rounds, how do smaller companies compete ?
• How is Boston’s biotech ecosystem continuing to foster innovation, and what distinctive advantages will support its rebound?
• Massachusetts startups raised $10.2B in the first half of 2026. Where is that capital landing?
• Are venture backed startups still the demand engine here, or has big pharma become the market’s steadier tenant?
• Boston still asks $76.72 per SF against $64.30 in San Diego. Is that premium defensible in 2027?
• How is technology driving the demand for flexible, adaptable labs and GMP facilities that can evolve with science?
• In what ways has tenant demand for modular layouts, spec suites, and shorter lease terms reshaped leasing dynamics in 2026?
• Owners are investing in prebuilt lab suites and marketing beyond life sciences users. Is this approach is actually working?